Показать сокращенную информацию
dc.contributor.author | Seheda, Y. | en |
dc.contributor.author | Shevchuk, S. | en |
dc.contributor.author | Kuvikova, I. | en |
dc.contributor.author | Galiutina, O. | en |
dc.date.accessioned | 2020-02-11T09:00:31Z | |
dc.date.available | 2020-02-11T09:00:31Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Polymorphism of 5,10-methylenetetrahydrofolate reductase (C677T) in patients with antiphospholipid syndrome, its association with cardiovascular lesions / Y. Seheda, S. Shevchuk, I. Kuvikova, O. Galiutina // Ann. Rheum. Dis. : first published as 10.1136/annrheumdis-2018-eular. 5232 on 12 June. - 2018. - P. 686. | en |
dc.identifier.uri | https://dspace.vnmu.edu.ua/123456789/4340 | |
dc.description.abstract | The present study aimed to analyze the C677T mutation of the MTHFR gene and its association with endothelial dysfunction and clinical manifestations of cardiovascular lesions in APS. 82 patients with APS, including 34 (41.6%) with primary antiphospholipid syndrome (PAPS) and 48 (58.4%) with secondary antiphospholipid syndrome (SAPS) were studied. It was founded that the mutation of the C677T of the MTHFR gene is not a risk factor for the development of atherosclerotic vascular damage in patients with APS, due to the lack of associative interrelationships between the decrease of EDVD, increase of IMT, clinical manifestations on the one hand, and the MTHFR polymorphism on the other. | en |
dc.language.iso | en | en |
dc.subject | antiphospholipid syndrome | en |
dc.subject | polymorphism | en |
dc.subject | 5,10-methylenetetrahydrofolate reductase | en |
dc.subject | cardiovascular lesions | en |
dc.title | Polymorphism of 5,10-methylenetetrahydrofolate reductase (C677T) in patients with antiphospholipid syndrome, its association with cardiovascular lesions | en |
dc.type | Thesis | en |